Evaluation of eribulin and bevacizumab for the real world treatment of recurrent breast cancer

被引：0

作者：

Earashi, M. ^{[1
]}

Matsui, K. ^{[2
]}

Maeda, K. ^{[2
]}

Fukushima, W. ^{[3
]}

Shimada, K. ^{[4
]}

Shimizu, T. ^{[5
]}

Nozaki, Z. ^{[6
]}

Tanada, Y. ^{[6
]}

Oyama, K. ^{[7
]}

Nagata, T. ^{[8
]}

Tsuneda, A. ^{[9
]}

Yoshikawa, A. ^{[10
]}

Yoshida, T. ^{[11
]}

Kiyohara, K. ^{[12
]}

Iwata, K. ^{[13
]}

Ii, T. ^{[14
]}

机构：

[1] Yatsuo Gen Hosp, Dept Breast Suegery, Toyama, Japan

[2] Toyama Prefectural Cent Hosp, Depertment Surg, Toyama, Japan

[3] Takaoka City Hosp, Derartment Surg, Takaoka, Toyama, Japan

[4] Imizu Municipal Hosp, Dept Surg, Imizu, Toyama, Japan

[5] Saiseikai Toyama Hosp, Dept Surg, Toyama, Japan

[6] Toyama Red Cross Hosp, Dept Surg, Toyama, Japan

[7] Kouseiren Takaoka Hosp, Dept Surg, Takaoka, Toyama, Japan

[8] Toyama Univ Hosp, Dept Surg, Toyama, Japan

[9] Toyama Rosai Hosp, Dept Surg, Uozu, Toyama, Japan

[10] Toyama City Hosp, Dept Surg, Toyama, Japan

[11] Saiseikai Takaoka Hosp, Dept Surg, Takaoka, Toyama, Japan

[12] Tonami Gen Hosp, Dept Surg, Tonami, Toyama, Japan

[13] Kurobe City Hosp, Dept Surg, Kurobe, Japan

[14] Kouseiren Namerikawa Hosp, Dept Surg, Namerikawa, Japan

来源：

ANNALS OF ONCOLOGY | 2017年 / 28卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

110P

引用

页码：32 / 32

页数：1

共 50 条

[21] Eribulin in heavily pretreated metastatic breast cancer: A real-world data from India
Mandal, T. K.
Bajpai, J.
Kapoor, A.
Kumar, A.
Ghosh, J.
Gulia, S.
Rath, S.
Gupta, S.
ANNALS OF ONCOLOGY, 2020, 31 : S1264 - S1264
[22] Systematic review of Real-World effectiveness of eribulin for locally advanced or metastatic breast cancer
Chabot, Isabelle
Zhao, Qi
Su, Yun
CURRENT MEDICAL RESEARCH AND OPINION, 2020, 36 (12) : 2025 - 2036
[23] Utilization and outcomes of eribulin in triple negative metastatic breast cancer: Real-world findings
Kish, J. K.
Mougalian, S. S.
Copher, R.
McAllister, L.
Zhixiao, W.
Broscious, M.
CANCER RESEARCH, 2017, 77
[24] Eribulin mesylate in the treatment of metastatic breast cancer
Jain, Sarika
Cigler, Tessa
BIOLOGICS-TARGETS & THERAPY, 2012, 6 : 21 - 29
[25] Economic evaluation of eribulin in the treatment of triple negative breast cancer in the United Kingdom
Wex, J.
Bodnar, C.
Simon, C.
Fernandes, F.
Tanova, N.
ANNALS OF ONCOLOGY, 2018, 29 : 114 - 114
[26] Real World Data on the Treatment of Patients with metastatic Breast Cancer with Eribulin in oncological Specialised Practices in Germany 2016-2020
Weide, R.
Wierecky, J.
Knoblich, J.
Vehling-Kaiser, U.
Mueller, L.
Otremba, B.
Schmalfeld, M.
Doerfel, S.
Karcher, A.
Rothe, A.
Schmidt, B.
Tamm, I
Hensel, M.
Feiten, S.
ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 107 - 108
[27] The Place for Eribulin in the Treatment of Metastatic Breast Cancer
William J. Gradishar
Current Oncology Reports, 2011, 13 : 11 - 16
[28] Clinical impact of eribulin in the treatment of breast cancer
Schwartzberg, Lee S.
BREAST CANCER MANAGEMENT, 2014, 3 (06) : 507 - 519
[29] The Place for Eribulin in the Treatment of Metastatic Breast Cancer
Gradishar, William J.
CURRENT ONCOLOGY REPORTS, 2011, 13 (01) : 11 - 16
[30] Pneumonia induced by eribulin mesylate in a patient with recurrent breast cancer
Ishida, Hiroo
Homma, Tetsuya
Ishida, Koko
Sugiyama, Tomohide
Kusumoto, Sojiro
Shirai, Takao
Nakashima, Masanao
Ohnishi, Tsukasa
Hirose, Takashi
INTERNATIONAL CANCER CONFERENCE JOURNAL, 2013, 2 (03): : 135 - 138

← 1 2 3 4 5 →